The U.S. Food and Drug Administration (FDA) this week announced an immediate review of new clinical trials involving the transfer of live cells from U.S. citizens to China and other “hostile” countries for genetic engineering, followed by reinfusion into American patients. The agency noted that, in some cases, this process occurred without the informed consent of the participants. The FDA stated that this action was prompted by evidence suggesting that certain trials failed to disclose the international transfer and processing of biological samples to subjects, potentially exposing sensitive U.S. genetic data to misuse by foreign governments, including adversarial nations.<\/p>\n\n\n\n